On April 9, the FDA approved Evenity (romosozumab-aqqg) to treat osteoporosis in postmenopausal women at high risk of fracture.
Read more at FDA.gov.
© 2019 HealthCom Media
All rights reserved. No part of this website or publication may be reproduced, stored, or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the copyright holder